Prognostic value of E-cadherin expression in non-small cell lung cancer treated with gefitinib

Oncology Research

Volumn 18, Issue 9, 2010, Pages 445-451

  Kook, Eun Hee ^a   Kim, Yeo Myeong ^a   Kim, Hyeon Tae ^a   Koh, Jae Soo ^a   Choi, Yun Jung ^a   Rho, Jin Kyung ^a   Kim, Hye Ryoun ^a   Kim, Cheol Hyeon ^a   Lee, Jae Cheol ^a  

^a Korea Cancer Center Hospital   (South Korea)

Author keywords

E cadherin; Epidermal growth factor receptor; Gefitinib; Lung cancer

Indexed keywords

GEFITINIB; UVOMORULIN;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; CANCER CELL CULTURE; CANCER CONTROL; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DRUG RESPONSE; DRUG SENSITIVITY; FEMALE; HUMAN; HUMAN TISSUE; IC 50; INOPERABLE CANCER; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; TREATMENT OUTCOME; TUMOR BIOPSY;

EID: 77952330648     PISSN: 09650407     EISSN: None     Source Type: Journal    
DOI: 10.3727/096504010X12671222663674     Document Type: Article

References (18)

1. Chang, A. Y. The role of gefitinib in the management of Asian patients with non-small cell lung cancer. Expert Opin. Investig. Drugs 17:401-411; 2008.
2. Chan, S. K.; Gullick, W. J.; Hill, M. E. Mutations of the epidermal growth factor receptor in non-small cell lung cancer - search and destroy. Eur. J. Cancer 42:17-23; 2006.
3. Karamouzis, M. V.; Grandis, J. R.; Argiris, A. Therapies directed against epidermal growth factor receptor in aero-digestive carcinomas. JAMA 298:70-82; 2007.
4. Sequist, L. V.; Bell, D. W.; Lynch, T. J.; Haber, D. A. Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer. J. Clin. Oncol. 25:587-595; 2007.
5. Greenburg, G.; Hay, E. D. Epithelia suspended in collagen gels can lose polarity and express characteristics of migrating mesenchymal cells. J. Cell Biol. 95:333-339; 1985.
6. Thiery, J. P. Epithelial-mesenchymal transitions in tumour progression. Nat. Rev. Cancer 2:442-454; 2002.
7. Yang, A. D.; Fan, F.; Camp, E. R.; van Buren, G.; Liu, W.; Somcio, R.; Gray, M. J.; Cheng, H.; Hoff, P. M.; Ellis, L. M. Chronic oxaliplatin resistance induces epithelial-to-mesenchymal transition in colorectal cancer cell lines. Clin. Cancer Res. 12:4147-4153; 2006.
8. Hiscox, S.; Jiang, W. G.; Obermeier, K.; Taylor, K.; Morgan, L.; Burmi, R.; Barrow, D.; Nicholson, R. I. Tamoxifen resistance in MCF7 cells promotes EMT-like behaviour and involves modulation of beta-catenin phosphorylation. Int. J. Cancer 118:290-301; 2006.
9. Thomson, S.; Buck, E.; Petti, F.; Griffin, G.; Brown, E.; Ramnarine, N.; Iwata, K. K.; Gibson, N.; Haley, J. D. Epithelial to mesenchymal transition is a determinant of sensitivity of non-small-cell lung carcinoma cell lines and xenografts to epidermal growth factor receptor inhibition. Cancer Res. 65:9455-9462; 2005.
10. Miyanaga, A.; Gemma, A.; Ando, M.; Kosaihira, S.; Noro, R.; Minegishi, Y.; Kataoka, K.; Nara, M.; Okano, T.; Miyazawa, H.; Tanaka, T.; Yoshimura, A.; Kobayashi, K.; Iwanami, H.; Hagiwara, K.; Tsuboi, E.; Kudoh, S. E-cadherin expression and epidermal growth factor receptor mutation status predict outcome in non-small cell lung cancer patients treated with gefitinib. Oncol. Rep. 19:377-383; 2008.
11. Yauch, R. L.; Januario, T.; Eberhard, D. A.; Cavet, G.; Zhu, W.; Fu, L.; Pham, T. Q.; Soriano, R.; Stinson, J.; Seshagiri, S.; Modrusan, Z.; Lin, C. Y.; O'Neill, V.; Amler, L. C. Epithelial versus mesenchymal phenotype determines in vitro sensitivity and predicts clinical activity of erlotinib in lung cancer patients. Clin. Cancer Res. 11: 8686-8698; 2005.
12. Cappuzzo, F.; Hirsch, F. R.; Rossi, E.; Bartolini, S.; Ceresoli, G. L.; Bemis, L.; Haney, J.; Witta, S.; Danenberg, K.; Domenichini, I.; Ludovini, V.; Magrini, E.; Gregorc, V.; Doglioni, C.; Sidoni, A.; Tonato, M.; Franklin, W. A.; Crino, L.; Bunn, Jr., P. A.; Varella-Garcia, M. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J. Natl. Cancer Inst. 97:643-655; 2005.
13. Buck, E.; Eyzaguirre, A.; Barr, S.; Thompson, S.; Sennello, R.; Young, D.; Iwata, K. K.; Gibson, N. W.; Cagnoni, P.; Haley, J. D. Loss of homotypic cell adhesion by epithelial-mesenchymal transition or mutation limits sensitivity to epidermal growth factor receptor inhibition. Mol. Cancer Ther. 6:532-541; 2007.
14. Liu, D.; Huang, C.; Kameyama, K.; Hayashi, E.; Yamauchi, A.; Kobayashi, S.; Yokomise, H. E-cadherin expression associated with differentiation and prognosis in patients with non-small cell lung cancer. Ann. Thorac. Surg. 71:949-954; 2001.
15. Bremnes, R. M.; Veve, R.; Gabrielson, E.; Hirsch, F. R.; Baron, A.; Bemis, L.; Gemmill, R. M.; Drabkin, H. A.; Franklin, W. A. High-throughput tissue microarray analysis used to evaluate biology and prognostic significance of the E-cadherin pathway in non-small-cell lung cancer. J. Clin. Oncol. 20:2417-2428; 2002.
16. Wu, J. Y.; Yu, C. J.; Yang, C. H.; Chiu, Y. H.; Gow, C. H.; Chang, Y. C.; Hsu, Y. C.; Wei, P. F.; Shih, J. Y.; Yang, P. C. First or second-line therapy with gefitinib produces equal survival in non small cell lung cancer. Am. J. Respir. Crit. Care Med. 178:847-853; 2008.
17. Yang, C. H. EGFR tyrosine kinasse inhibitors for the treatment of NSCLC in East Asia: Present and future. Lung Cancer 60:S23-30; 2008.
18. Rho, J. K.; Choi, Y. J.; Lee, J. K.; Ryoo, B. Y.; Na, I. I.; Yang, S. H.; Kim, C. H.; Lee, J. C. Epithelial to mesenchymal transition derived from repeated exposure to gefitinib determines the sensitivity to EGFR inhibitors in A549, a non-small cell lung cancer cell line. Lung Cancer 63:219-226; 2009.